Table 1 Patients characteristics
Characteristic | Icotinib (n = 21) | Gefitinib (n = 22) | P value |
|---|---|---|---|
Age | |||
 Median | 63 | 61 |  |
 Range | 39 to 81 | 41 to 79 |  |
Years | |||
  < 65 | 12 (57.1%) | 14 (63.6%) | 0.66 |
  ≥ 65 | 9 (42.9%) | 8 (36.4%) |  |
Sex | |||
 Male | 8 (38.1%) | 2 (9.1%) | 0.06 |
 Female | 13 (61.9%) | 20 (90.9%) |  |
ECOG PS | |||
 0–1 | 13 (61.9%) | 16 (72.7%) | 0.45 |
 2 or more | 8 (38.1%) | 6 (27.3%) |  |
Smoking | |||
 Yes | 7 (33.3%) | 2 (9.1%) | 0.11 |
 No | 14 (66.7%) | 20 (90.9%) |  |
Pleural effusion | |||
 Yes | 8 (38.1%) | 9 (40.9%) | 0.85 |
 No | 13 (61.9%) | 13 (59.1%) |  |
Metastatic organs | |||
 1 | 4 (19.1%) | 3 (13.6%) | 0.95 |
 2 or more | 17 (80.9%) | 19 (86.4%) |  |
Number of brain metastases | |||
Single | 2 (9.5%) | 5 (22.7%) | 0.45 |
Multiple | 19 (90.5%) | 17 (77.3%) | Â |
Size of brain metastases | |||
  ≥ 20 mm | 9 (42.9%) | 4 (18.2%) | 0.08 |
  < 20 mm | 12 (57.1%) | 18 (81.8%) |  |
Brain radiation therapy | |||
 Yes | 5 (23.8%) | 3 (13.6%) | 0.64 |
 No | 16 (76.2%) | 19 (86.4%) |  |
EGFR mutation status | |||
 Exon 19 del | 10 (47.6%) | 10 (45.5%) | 0.89 |
 Exon 21 L858R | 11 (52.4%) | 12 (54.5%) |  |
Previous chemotherapy | |||
Yes | 5 (23.8%) | 2 (9.1%) | 0.37 |
No | 16 (76.2%) | 20 (90.9%) | Â |